Abstract

ObjectivesIn a post-hoc analysis, we aimed to validate the Lupus Low Disease Activity State (LLDAS) definition as an endpoint in an systemic lupus erythematosus (SLE) Phase IIb randomised controlled trial...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
OP0001 The lupus low disease activity state (LLDAS) definition discriminates responders in a systemic lupus erythematosus (SLE) trial: post-hoc analysis of the phase iib muse trial of anifrolumab
E Morand ... T Sheytanova
Annals of the Rheumatic Diseases | VOL. 76
E Morand, et. al.E Morand ... T Sheytanova
01 Jun 2017
Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus
Eric F Morand ... Vera Golder
Annals of the Rheumatic Diseases | VOL. 10
Eric F Morand, et. al.Eric F Morand ... Vera Golder
23 Jan 2023
Performance of SLE responder index and lupus low disease activity state in real life: A prospective cohort study.
Giuseppe A Ramirez ... Angelo A Manfredi
APLAR Journal of Rheumatology | VOL. 22
Giuseppe A Ramirez, et. al.Giuseppe A Ramirez ... Angelo A Manfredi
05 Aug 2019
209 Attainment of low disease activity and remission with atacicept in patients with systemic lupus erythematosus and high disease activity in the phase IIb ADDRESS II study and its long-term extension
Eric Morand ... Cristina Vazquez-Mateo
-
Eric Morand, et. al.Eric Morand ... Cristina Vazquez-Mateo
01 Apr 2019
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
Itaconate is a metabolic regulator of bone formation in homeostasis and arthritis
Markus Kieler ... Stephan Blüml
Annals of the Rheumatic Diseases | VOL. -
Markus Kieler, et. al.Markus Kieler ... Stephan Blüml
10 Jul 2024
Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials
Matthew A Brown ... Irene Van Der Horst-Bruinsma
Annals of the Rheumatic Diseases | VOL. -
Matthew A Brown, et. al.Matthew A Brown ... Irene Van Der Horst-Bruinsma
08 Jul 2024
Efficacy and safety of first-line biological DMARDs in rheumatoid arthritis patients with chronic kidney disease
Yusuke Yoshimura ... Naoki Sawa
Annals of the Rheumatic Diseases | VOL. -
Yusuke Yoshimura, et. al.Yusuke Yoshimura ... Naoki Sawa
04 Jul 2024
Acod1-mediated inhibition of aerobic glycolysis suppresses osteoclast differentiation and attenuates bone erosion in arthritis
Katerina Kachler ... Aline Bozec
Annals of the Rheumatic Diseases | VOL. -
Katerina Kachler, et. al.Katerina Kachler ... Aline Bozec
04 Jul 2024
View more papers